One of Dr. Fogarty’s strengths when forming new companies was a focus on hiring experts in the field who had the ability to both embrace and expand on his vision. Such was the case when he asked Gary Kalbach to help him start the Fogarty Institute for Innovation in 2007. He became founding president and chair of the board,
“I don’t believe in the concept of the ‘lone genius’ that journalists like to highlight when writing about the success of a company – it’s really the teams that win.”
This year’s 21stAnnual Thomas J. Fogarty, MD, Lecture held at Stanford University, featured Brook Byers, founding partner of Kleiner Perkins.
Going to the doctor is not always a preferred activity, and part of that is the testing involved, including, of course, the ubiquitous urine test. This remains a standard method used to determine the proper course of treatment for patients and to prevent exposure to potentially harmful medications and procedures. Point-of-care urine tests are used to diagnose a range of conditions,
Entrepreneurship runs in Fletcher Wilson’s veins – quite literally. As founder and CEO of InterVene, a Fogarty Institute graduate that has developed a minimally invasive device for the treatment of severe venous disease in the legs, Fletcher has many of the traits that make a successful leader and innovator. That includes a penchant for identifying problems and finding solutions,
Seemingly intractable issues often have simple, elegant solutions when approached with creativity. That’s what Eric Chehab, Ph.D., has found in his work designing products that solve problems in neonatal care.
As the newest addition to the Ferolyn Fellowship class, he has already attained notable accomplishments in his young career, including co-founding and spearheading Novonate.
Edwards Lifesciences’ first and only chairman and CEO, Mike Mussallem, is the leading force behind the company’s success and committed culture of giving back to global communities.
Widely recognized as being at the forefront of patient-focused medical innovations for structural heart disease and critical care monitoring, the company has seen its value jump 4,000 percent and employment double to more than 13,000 in the past 18 years,
Raydiant Oximetry, a Fogarty Institute company that is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth, has closed a $5.6 million Series A funding round led by VCapital. It follows on the heels of a recent string of funding rounds, grants and an exit by fellow Fogarty companies Enspectra,
Since its inception four years ago, the Fogarty Institute’s FDA Fellowship program has blossomed into a successful, ongoing partnership that is being lauded on both sides for enhancing the understanding, communication and collaboration between entrepreneurs and regulators. To date, the Institute has hosted 41 Fellows in addition to FDA scientists and department heads.
The relationship has proven to be beneficial for both sides: The FDA better understands the challenges inherent in device development,
From consulting to the Stanford Biodesign program, Andy McGibbon has had a front-row seat to how innovation can advance the healthcare field. And now he is delighted to join the Ferolyn Fellowship as a way to further explore the medtech ecosystem, thus enhancing his newest undertaking, Sonder Capital, a venture firm focused on early-stage medtech startups.
With more than 10,000 heart operations under his belt, Dr. Vincent Gaudiani is one of the most prolific practitioners in cardiovascular surgery. His early career followed a similar path as Dr. Fogarty’s, and the two later met at Stanford and have been colleagues and steadfast friends ever since.
Dr. Gaudiani received his bachelor’s degree in English from Harvard University,